PMV Pharmaceuticals, Inc.
PMVP
$1.48
$0.010.68%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 4.48M | 4.12M | 11.40M | 4.94M | 5.54M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 22.88M | 21.56M | 25.17M | 21.89M | 20.17M |
Operating Income | -22.88M | -21.56M | -25.17M | -21.89M | -20.17M |
Income Before Tax | -21.21M | -19.63M | -23.00M | -19.15M | -17.39M |
Income Tax Expenses | 5.00K | -2.20M | 0.00 | 74.00K | -16.17M |
Earnings from Continuing Operations | -21.21M | -17.44M | -23.00M | -19.23M | -1.21M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -21.21M | -17.44M | -23.00M | -19.23M | -1.21M |
EBIT | -22.88M | -21.56M | -25.17M | -21.89M | -20.17M |
EBITDA | -22.85M | -21.53M | -25.13M | -21.52M | -19.80M |
EPS Basic | -0.41 | -0.34 | -0.44 | -0.37 | -0.02 |
Normalized Basic EPS | -0.25 | -0.24 | -0.28 | -0.23 | -0.21 |
EPS Diluted | -0.41 | -0.34 | -0.44 | -0.37 | -0.02 |
Normalized Diluted EPS | -0.25 | -0.24 | -0.28 | -0.23 | -0.21 |
Average Basic Shares Outstanding | 52.01M | 51.95M | 51.82M | 51.57M | 51.48M |
Average Diluted Shares Outstanding | 52.01M | 51.95M | 51.82M | 51.57M | 51.48M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |